FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330339568> ?p ?o ?g. }

• W2330339568 endingPage "663" @default.
• W2330339568 startingPage "663.2" @default.
• W2330339568 abstract "<h3>Background</h3> Mycobacterium Tuberculosis (TB) infection is one of the typical adverse events during the treatment with biologics, especially anti-tumour necrosis factor (TNF) agents, in patients with rheumatic disease. The screening of latent TB infection before treatment with biologics is recommended in a lot of recommendations including ACR recommendation and recommendation in European countries. Several methods of screening latent TB infection are used in clinical practice and QuantiFERON (QFT) is one of them. Although QFT-2G was old type, QFT-3G was newly developed. Differences in characters between these two methods are not well understood. <h3>Objectives</h3> The objectives of this study are to compare QFT-2G and 3G as screening for latent TB infection in patients with rheumatoid arthritis (RA) before treatment with biologics and investigate the outcome after initiation of biologics treatment. <h3>Methods</h3> RA patients in whom QFT-2G or 3G was performed in our department were included in this study. Patient characteristics and result of QFT were compared between 2G group and 3G group. Chest CT findings and clinical course after initiation of biologics were investigated in patients with positive QFT. <h3>Results</h3> 178 cases and 57 cases were included in 2G group and 3G group, respectively. Mean age in 2G group and 3G group were 59.3 years old and 60.4 years old, respectively. 5 cases in 2G group have past history of TB infection and none in 3G group. 5 cases in 2G group (2.8%) and 6 cases in 3G group (10.5%) have positive results and there was a significant difference (p=0.027). 157 cases in 2G group (88.2%) and 42 cases in 3G group (73.7%) have negative results and there was a significant difference (p=0.011). In 10 cases that had positive results of QFT 2G or 3G, none had past history of TB, chest CT was normal in 4 cases and chemoprophylaxis of isoniazid (INH) was performed in 5 cases. Although biologics was used in 7 cases among 10 QFT-positive cases, no active TB was occurred until last observation. Used biologics were infliximab in 2 cases, etanercept in a case, abatacept in 3 cases and golimumab in a case. <h3>Conclusions</h3> Although higher positive rate and lower negative rate were seen in QFT-3G group compared with in QFT-2Ggroup, its usefulness in clinical practice is unknown. QFT-3G has high sensitivity and patients who were prescribed with INH are increased. There are several adverse events including hepatic toxicity in INH chemoprophylaxis. This study suggested that biologics therapy with INH chemoprophylaxis was acceptable in RA patients with positive QFT if they had no findings of suspected active TB in clinical sign or chest X-P and CT. <h3>Disclosure of Interest</h3> None Declared" @default.
• W2330339568 created "2016-06-24" @default.
• W2330339568 creator A5013176183 @default.
• W2330339568 creator A5017609785 @default.
• W2330339568 creator A5077876808 @default.
• W2330339568 creator A5086204817 @default.
• W2330339568 date "2013-06-01" @default.
• W2330339568 modified "2023-09-26" @default.
• W2330339568 title "AB0446 A comparative study of quantiferon TB-2G and 3G as screening examination for latent mycobacterium tuberculosis infection in patients with rheumatoid arthritis before treatment with biologics" @default.
• W2330339568 doi "https://doi.org/10.1136/annrheumdis-2012-eular.446" @default.
• W2330339568 hasPublicationYear "2013" @default.
• W2330339568 type Work @default.
• W2330339568 sameAs 2330339568 @default.
• W2330339568 citedByCount "0" @default.
• W2330339568 crossrefType "journal-article" @default.
• W2330339568 hasAuthorship W2330339568A5013176183 @default.
• W2330339568 hasAuthorship W2330339568A5017609785 @default.
• W2330339568 hasAuthorship W2330339568A5077876808 @default.
• W2330339568 hasAuthorship W2330339568A5086204817 @default.
• W2330339568 hasConcept C126322002 @default.
• W2330339568 hasConcept C142724271 @default.
• W2330339568 hasConcept C203014093 @default.
• W2330339568 hasConcept C2776763545 @default.
• W2330339568 hasConcept C2777575956 @default.
• W2330339568 hasConcept C2777975735 @default.
• W2330339568 hasConcept C2779806340 @default.
• W2330339568 hasConcept C2781069245 @default.
• W2330339568 hasConcept C71924100 @default.
• W2330339568 hasConceptScore W2330339568C126322002 @default.
• W2330339568 hasConceptScore W2330339568C142724271 @default.
• W2330339568 hasConceptScore W2330339568C203014093 @default.
• W2330339568 hasConceptScore W2330339568C2776763545 @default.
• W2330339568 hasConceptScore W2330339568C2777575956 @default.
• W2330339568 hasConceptScore W2330339568C2777975735 @default.
• W2330339568 hasConceptScore W2330339568C2779806340 @default.
• W2330339568 hasConceptScore W2330339568C2781069245 @default.
• W2330339568 hasConceptScore W2330339568C71924100 @default.
• W2330339568 hasIssue "Suppl 3" @default.
• W2330339568 hasLocation W23303395681 @default.
• W2330339568 hasOpenAccess W2330339568 @default.
• W2330339568 hasPrimaryLocation W23303395681 @default.
• W2330339568 hasRelatedWork W13777425 @default.
• W2330339568 hasRelatedWork W169620549 @default.
• W2330339568 hasRelatedWork W2025404538 @default.
• W2330339568 hasRelatedWork W2049082850 @default.
• W2330339568 hasRelatedWork W2118252327 @default.
• W2330339568 hasRelatedWork W2604543294 @default.
• W2330339568 hasRelatedWork W2740017267 @default.
• W2330339568 hasRelatedWork W2904701318 @default.
• W2330339568 hasRelatedWork W2956353651 @default.
• W2330339568 hasRelatedWork W2607486105 @default.
• W2330339568 hasVolume "71" @default.
• W2330339568 isParatext "false" @default.
• W2330339568 isRetracted "false" @default.
• W2330339568 magId "2330339568" @default.
• W2330339568 workType "article" @default.